PET-Guided strategy may improve outcomes in aggressive lymphoma
NCT ID NCT00498043
First seen Nov 01, 2025 · Last updated May 15, 2026 · Updated 28 times
Summary
This study tested two different chemotherapy combinations (R-ACVBP and R-CHOP) along with the targeted drug rituximab in 222 adults aged 18-59 with an aggressive type of B-cell lymphoma. Participants had 2 or 3 risk factors that make the disease harder to treat. The researchers used PET scans after the second and fourth treatment cycles to decide which patients needed more intensive therapy. The goal was to see which combination worked better and whether a PET-guided approach could improve complete response rates.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for LYMPHOMA, B-CELL are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
René Olivier Casasnovas
Dijon, 21000, France
Conditions
Explore the condition pages connected to this study.